<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310270</url>
  </required_header>
  <id_info>
    <org_study_id>10-04615</org_study_id>
    <nct_id>NCT01310270</nct_id>
  </id_info>
  <brief_title>The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation</brief_title>
  <acronym>OMEGA-PAD</acronym>
  <official_title>The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis being tested is that in patients with stable claudication and documented PAD,
      omega-3 supplementation for 1 month will lead to improvement in endothelial function as
      measured by flow-mediated, brachial artery vasodilation (FMD), as well as improvement in the
      vascular inflammatory profile as measured by a panel of established circulating inflammatory
      biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>1 month</time_frame>
    <description>Flow-mediated, brachial artery vasodilation (FMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bio-markers</measure>
    <time_frame>1 month</time_frame>
    <description>Inflammatory bio-markers: C-reactive protein (hsCRP), interleukin-6 (IL-6), soluble intracellular adhesion molecule-1 (sICAM-1) and the anti-inflammatory mediator 15-epimeric lipoxin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Pro-Omega</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose, short-duration dietary omega-3 fatty acids supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pro-Omega</intervention_name>
    <description>Pro-Omega, 4.4gm/day x 1 month</description>
    <arm_group_label>Pro-Omega</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 Fatty Acid</intervention_name>
    <description>4.4 gm/day for 1 month</description>
    <arm_group_label>Pro-Omega</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  intermittent claudication

          -  resting or exercise Ankle-Brachial Index (ABI) &lt;0.9

          -  age 50 and more

        Exclusion Criteria:

          -  critical limb ischemia

          -  hypersensitivity/allergies to fish or seafood

          -  already on omega-3 fatty acids or equivalent

          -  significant renal, hepatic, and inflammatory disease

          -  concurrent severe infections

          -  acute illness (MI, stroke, major surgery within 30 days)

          -  receiving immunosuppressive medications or steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Grenon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>March 2, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
